GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Business & Industry
- AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
- Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
Research & Development
- Preventing 'cytokine storm' may ease severe COVID-19 symptoms
- Official COVID-19 deaths underestimate the full impact of the pandemic
- Local climate unlikely to drive the early COVID-19 pandemic
- Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19
- Antibody neutralizes SARS and COVID-19 coronaviruses
- Early indicators of vaccine efficacy
- Arthritis drug may improve respiratory function in some patients with severe COVID-19
Conferences & Events
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
Regulatory Affairs
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
- FDA reiterates importance of close patient supervision for 'off-label' use of antimalarial drugs
- FDA encourages recovered patients to donate plasma for development of blood-related therapies